Celladon Corporation

1.15

0.0000

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：1.15

开：1.15

低：1.15

收：1.15

52周最高：26.17

52周最低：0.8600

股本：- -

流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

信达生物IBI343（CLDN 18.2抗体药物偶联物）在澳大利亚完成首例受试者给药

美通社

·

2022/10/31

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CLDN/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"CLDN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDN\",,,,,undefined,":{"symbol":"CLDN","market":"US","secType":"STK","nameCN":"Celladon Corporation","latestPrice":1.15,"timestamp":1459195200000,"preClose":1.15,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"盘后交易","change":0,"latestTime":"02-23 17:43:45 EST","open":1.15,"high":1.15,"low":1.15,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771894800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.15,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDN\",,,,,undefined,":{"symbol":"CLDN","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":1.15,"amplitude":0,"preClose":1.15,"low":1.15,"week52Low":0.86,"pbRate":"--","week52High":26.17,"institutionHeld":0,"latestPrice":1.15,"eps":0,"divideRate":0,"volume":0,"delay":0,"open":1.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLDN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLDN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLDN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLDN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2279242198","title":"信达生物IBI343（CLDN 18.2抗体药物偶联物）在澳大利亚完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2279242198","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2279242198?lang=zh_cn&edition=fundamental","pubTime":"2022-10-31 08:00","pubTimestamp":1667174400,"startTime":"0","endTime":"0","summary":"IBI343是重组人源抗CLDN18.2 ADC，与表达CLDN18.2的肿瘤细胞结合后，可发生CLDN18.2依赖性ADC内化，并释放毒素药物引起DNA损伤，导致肿瘤细胞凋亡。我们很高兴IBI343在澳大利亚的临床1期研究已完成首例受试者给药，期待IBI343在晚期实体瘤试者中获得积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3918251_ZH18251_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1589","BK1161","01801","IVBIY","CLDN","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}